Abstract: A fluid injection system including a graphical user interface, a fluid control module operatively connected to the graphical user interface, a monitoring control module provided in at least one of the graphical user interface and the fluid control module, a fluid injector operatively connected to the graphical user interface and the fluid control module, at least one fluid path set in fluid communication with the fluid control module, and a hemodynamic monitoring system operatively connected to the fluid path set and the monitoring control module. The hemodynamic monitoring system may be configured to receive electrical signals regarding pressure waves formed in medical fluid directed through the fluid path set based on a location of the fluid path set in a patient's vasculature, to convert the electrical signals to pressure wave form information, and to send the pressure wave form information to the monitoring control module.

Abstract: A fluid delivery device includes: a fluid-filled cartridge comprising an outlet; a syringe comprising a substantially cylindrical syringe barrel having an open end and a fluid dispensing end; and a plunger rod configured to be received within the open end of the syringe barrel. The plunger rod comprises: a first end having a sealing member provided in sealing engagement with an inner wall of the syringe barrel such that a first syringe chamber is provided between the first end of the plunger rod and the fluid dispensing end of the syringe barrel; a second end extending out of the open end of the syringe barrel and having a cartridge-receiving chamber having a connection mechanism positioned therein for connecting the outlet of the cartridge thereto. The plunger rod also includes a fluid channel extending from the connection mechanism to the first end of the plunger rod.

Abstract: The present disclosure relates to automated systems and methods which assess the quality of radiology examinations and identify actionable changes to improve the quality of future exams. For each of a plurality of imaging studies, a study protocol and set of study metrics can be defined and the defined study protocol can be performed to generate data associated with the imaging study. A metrics assessment can be performed by applying at least a portion of the data associated with the result of the imaging study against the set of study metrics for the imaging study so as to generate a metrics score for the imaging study. The metrics scores can be stored in a score repository and analyzed so as to provide recommendations to improve the examination process.

Abstract: A syringe includes a body and a plunger movably disposed within the body. The syringe may be used with an injector including a drive member. The drive member preferably includes at least one pin adapted to form a retractable abutting connection with an interior of a plunger to enable the drive member to retract the plunger with the body of the syringe.

Abstract: A calibration system for calibrating a pressure output of a fluid injector having a housing configured for connecting to the fluid injector; a drive member engagement portion configured for contacting a drive member of the fluid injector; a compressible member, which may have a known modulus of compression, connected at its proximal end to the drive member engagement portion, wherein the compressible member is compressed with movement of the drive member of the fluid injector between a first, uncompressed position and a second, at least partially compressed position of the fluid injector in a distal direction; and a sensor connected to the compressible member is described. The sensor is configured for measuring at least one of a force imparted by the drive member and a displacement of the drive member when the compressible member is in the second, at least partially compressed position.

Abstract: Disclosed herein is a sterilizable adapter for a cell culture vessel comprising a body, an upper connection and/or a lid, at least one port, a ventilation passage, a lower internal connection suitable for connection to a cell culture vessel and a cell retention device and/or a cell separation device as well as a device comprising said sterilizable adapter and a method for cell cultivation using said sterilizable adapter.

Abstract: The present invention relates to an arrangement comprising an intrauterine system, an inserter for the intrauterine system and a package for the inserter.

Abstract: A syringe includes a barrel having a distal end, a proximal end, and a sidewall extending therebetween along a longitudinal axis. At least one engagement member protrudes from a terminal portion of the sidewall in a proximal direction along the longitudinal axis. The at least one engagement member tapers axially in a direction from the distal end toward the proximal end. The at least one engagement member is configured for engagement with a locking mechanism of a fluid injector to releasably lock the syringe with the fluid injector. A taper of the at least one engagement member is configured to rotationally guide the syringe into alignment with the locking mechanism and axially eject the syringe upon rotation of the syringe. The locking mechanism operatively engages the at least one engagement member regardless of an orientation of the syringe about the longitudinal axis relative to the injector.

Abstract: A diagnostic contrast composition includes a carrier fluid and a non-decaying gas-evolving fluid incorporated in the carrier fluid. The gas-evolving fluid has a vapor pressure sufficient to evolve the gas from a circulatory system within a lung of a patient. The gas-evolving fluid is a composition containing a sufficient quantity of atoms with an atomic number higher than 8 to provide an increased absorption sufficient to increase a Hounsfield Unit measurement in an image in a CT imaging system. The gas-evolving fluid is selected from the group consisting of xenon gas, krypton gas, sulfur hexafluoride, a perfluorocarbon, a brominated perfluorocarbon, and combinations thereof. The carrier fluid is selected from the group consisting of water, saline, saline comprising one or more blood proteins, and saline comprising dissolved lipids.

Abstract: Aspects of this invention inter alia relate to novel systems for targeting, editing or manipulating DNA in a cell, comprising one or more heterologous vector(s) encoding a SluCas9 nuclease from Staphylococcus lugdunensis or variants thereof, and one or more guide RNAs (gRNAs), or a SluCas9 nuclease or variant thereof and one or more gRNAs.

Abstract: This disclosure relates to methods for use in inactivating viruses. The methods of inactivating viruses with N-methylglucamides is applicable to the purification process of biologically-active drugs such as protein subunits, proteins (enzymes, factors, etc.), recombinant proteins, antibodies, vaccine or gene therapeutic products. The detergents used in this method are based on multiple N-methylglucamide homologs, consisting of a hydrophilic glucose moiety and hydrophobic fatty acid tail, linked by an amide bond. Additionally, these sugar-based detergents are nonionic by nature, which do not disrupt the drug protein, plasma biologies, non-enveloped viral vaccine or adeno associated viral particles.

Abstract: Described is an injector system for implementing a split bolus injection procedure. The injector system includes a processor and a non-transitory storage medium having programming instructions stored therein that, when executed by the processor, enable the injector system to operate as a parameter generation system for use in determining parameters associated with a split bolus injection protocol via which injection of the contrast agent by the injector system is controlled. The split bolus injection protocol includes at least a loading injection and a diagnostic injection, wherein the loading injection is performed before the diagnostic injection, and wherein a pause separates the loading injection from the diagnostic injection. Also described is a method for patient imaging using a split bolus injection technique and a system having an imaging device and the injector system described above.

Abstract: This disclosure relates to methods for the prevention of the reduction of disulfide bonds in a polypeptide expressed in a recombinant host cell, comprising, following fermentation, adding selenite and/or its salts or derivatives to a harvest solution of the recombinant host cell, wherein the disulfide bond in the polypeptide remains non-reduced.

Abstract: An engagement mechanism associated with a reciprocally movable piston of a fluid injector is configured for releasably engaging an engagement portion at a proximal end of a rolling diaphragm syringe having a flexible sidewall configured for rolling upon itself when acted upon by the piston. The engagement mechanism has a plurality of engagement elements reversibly and pivotally movable about a pivot pin relative to the engagement portion of the syringe between a first position, where the plurality of engagement elements are disengaged from the engagement portion of the syringe, and a second position, where the plurality of engagement elements are pivotally movable about the pivot pin in a radially inward direction to engage with the engagement portion of the syringe. The engagement mechanism further has a drive mechanism for moving the plurality of engagement elements between the first position and the second position.

Abstract: A plunger for use with a syringe has a plunger body with a proximal end, a distal end, and a circumferential sidewall extending between the proximal end and the distal end along a plunger longitudinal axis. The plunger further has at least one resiliently deflectable retaining member having a first segment attached to the plunger body and a second segment protruding toward the distal end of the plunger body and deflectable relative to the first segment. The plunger further has at least one actuation member associated with the at least one resiliently deflectable retaining member. The at least one actuation member interacts with a piston to deflect the at least one resiliently deflectable retaining member upon rotation of the plunger relative to the piston. The plunger is engageable with the piston regardless of a rotational orientation of the piston relative to the plunger.

Abstract: The present disclosure relates to oral naproxen sodium tablets comprising roller-compacted granules, methods of preparing thereof, and methods of using thereof. The naproxen sodium tablets are formulated for and prepared by dry granulation methods, specifically roller compaction. The combination of dry granulation compatible excipients with roller compaction methods results m naproxen sodium tablets that exhibit an enhanced dissolution profile and shorter disintegration time as compared to commercially available oral naproxen sodium tablets prepared by standard wet granulation methods.

Abstract: A fluid injector system includes a powered fluid injector, a connection port configured to receive a single-use disposable set having tubing connected to a fluid inlet port at a first end and connected to a waste outlet port at a second end, and a detector associated with the connection port and configured to generate a signal in response to a sonic, infrasonic, or ultrasonic wave emitted from the single-use disposable set during a priming operation of the single-use disposable set. In some examples, the detector is configured to generate a signal if the frequency of the wave emitted from the single-use disposable set is outside a predetermined range of frequencies corresponding to a predetermined range of frequencies of air expelled from the tubing. A method for detecting the multiple uses of a single-use disposable set connected to a fluid injector system is also provided.

Abstract: Provided herein, in some embodiments, are materials and methods for treating hemophilia A in a subject ex vivo or in vivo. Also provided herein, in some embodiments, are materials and methods for knocking in a coding sequence encoding a synthetic FVIII having a B domain substitute into a genome.

Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.